Findings from an initial cost analysis support further research and reconsideration of the role of computed tomography urography for imaging evaluation in patients with asymptomatic microhematuria, according to urologists from the University of Alabama at Birmingham.
Fewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.
Other pipeline developments discussed include a bladder cancer test, a male infertility assay, and the first oral dosage treatment for hypogonadism.
In this interview, Khurshid R. Ghani, MD, and David C. Miller, MD, MPH, discuss the origins of the Michigan Urological Surgery Improvement Collaborative, what it’s done for prostate cancer care in Michigan, and how a similar model could be rolled out nationally.
"There are significant data examining the role of heat exposure to male sperm. However, none of it is very high quality and the data are murky at best," write James R. Craig, MD, MS; William Brant, MD; and James M. Hotaling, MD, MS.
In the 2016 elections, a urologist was elected to the House of Representatives but overall physician representation in Congress has declined to just 3%.
“Our research shows that the implications of kidney stones may go beyond the discomfort they are so often associated with,” says co-lead author Andrew Rule, MD.
A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
UT blogger Lisa Kerr, PA-C, makes her case for using physician assistants to first assist on surgical procedures.
Urologist Henry Rosevear, MD, discusses a recent OR experience that had him rethink his value as a surgeon and consider a possible alternative to better align the financial incentives of the surgeon with the hospital's goals.
Urology resident, Amy Pearlman, MD, discusses how the experience of helping her mother go through radiation therapy changed how she is able to relate to her patients.
Testosterone replacement therapy may not have the benefit many physicians think it does-particularly for women grappling with sexual dysfunction.
Urology Times conducted a survey in June and July 2016 in which we sought urologists’ opinions on maintenance of certification. These charts provide a snapshot of their thoughts regarding the controversial program.
Ureteral reimplantation videos.
. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections
Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
The genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.
Two late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.
In this exclusive interview, Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid Services, discusses alternative payment models, outlines what resources are available for practices, and provides an overview of the three options practices have for participation in the Quality Payment Program.
Testosterone therapy in hypogonadal men with prostate cancer who have had definitive treatment and in those on surveillance appears to be safe, according to a new study.
An examination of data involving more than 63,000 PSA tests ordered by primary care physicians reveals some surprising findings.
A recent study shows children born to high-status parents have a higher incidence rate of developing prostate and other cancers in later life.
Urologists need to “be aware of the role and impact of [anabolic-androgenic steroid] use in our patient population,” says men’s health expert James M. Hotaling, MD, MS.
A team from Roswell Park Cancer Institute has developed and validated a quality assessment tool based on prospectively collected data on robot-assisted cystectomy.
Two days of discussions at the Sept. 7 and 8 meetings of the Medicare Payment Advisory Commission highlighted the difficulties and complexities that will face policymakers as they consider solutions to the financial crisis facing Medicare.
In this article, the the most recent installment in an ongoing series, Robert A. Dowling, MD, summarizes his first impressions of the MACRA final rule and what it means for urologists.
Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.